Journal profile · IMMUNOLOGYTOXICOLOGY-TOXICOLOGY
Inflammopharmacology
ISSN 0925-4692 · eISSN 1568-5608 · Springer International Publishing · NETHERLANDS · 6 issues per year · Founded 1991
Inflammopharmacology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 6.37; hybrid open access; APC about USD 4,990; median 53 days to acceptance (119 articles, last 24 months); 458 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Inflammopharmacology is published by Springer International Publishing and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Inflammatory mediators and NSAID effects, Rheumatoid Arthritis Research and Therapies and Pharmacological Effects of Natural Compounds, together about 24.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs Muscle-immune interactions during inflammation: mechanisms of inflammation and anti-inflammatory actions of therapeutic agents on skeletal muscle under conditions of aging or injury.Safety and efficacy of Non-prescription (OTC) and prescription NSAIDs and Analgesics
From the journal's Aims & Scope
Research area (LetPub): IMMUNOLOGYTOXICOLOGY-TOXICOLOGY
Editor-in-chief Kim D. RainsfordPublisher website
Editorial board by country: none in mainland China; most named United Kingdom 15, United States 12, Australia 12, Germany 4, Hungary 4 (70 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Inflammatory mediators and NSAID effectsMedicine10.4%
- Rheumatoid Arthritis Research and TherapiesMedicine7.6%
- Pharmacological Effects of Natural CompoundsPharmacology, Toxicology and Pharmaceutics6.4%
- Natural product bioactivities and synthesisBiochemistry, Genetics and Molecular Biology5.5%
- Helicobacter pylori-related gastroenterology studiesMedicine5.3%
- Pain Mechanisms and TreatmentsMedicine4.8%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience4.6%
- Inflammasome and immune disordersBiochemistry, Genetics and Molecular Biology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Toxicology | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Toxicology | Zone 1 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Toxicology | Zone 1 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.37LetPub ·
- Impact factor (publisher) 2025
- 6.3Publisher website ·
- 5-year impact factor (publisher) 2025
- 6Publisher website ·
- CiteScore 2026-06
- 8.7LetPub ·
- SJR 2026-06
- 1.37LetPub ·
- SNIP 2026-06
- 1.3LetPub ·
- h-index
- 45LetPub ·
- h-index
- 92OpenAlex ·
- i10-index
- 1,479OpenAlex ·
- 2-year mean citedness
- 5.29OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 20.41%LetPub ·
Volume
- Articles per year
- 445LetPub ·
- Downloads per year (publisher) 2025
- 1,200,000Publisher website ·
Articles by year OpenAlex count · 3,057 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 320 | 80 | 197 |
| 2025 | 458 | 108 | 2,474 |
| 2024 | 220 | 51 | 2,609 |
| 2023 | 273 | 104 | 5,244 |
| 2022 | 221 | 100 | 5,030 |
| 2021 | 114 | 35 | 3,225 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
53 daysMedian, submission to acceptance · P25–P75 30 days – 91 days
- Acceptance to online
- median 22 days (119 articles)
- Submission to online
- median 82 days
- Sample
- 119 articles with submission and acceptance dates (822 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 6 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,990 / EUR 3,890 / GBP 3,090 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Harvard
- Suggested reviewers
- Optional
Article types accepted4
- brief reportManuscripts can be in the form of (a) full length publications of Research; they should not be longer than 8 printed pages. This accounts for approx. 870 words …Length not stated
- correspondenceManuscripts can be in the form of (a) full length publications of Research; they should not be longer than 8 printed pages. This accounts for approx. 870 words …Length not stated
- editorialManuscripts can be in the form of (a) full length publications of Research; they should not be longer than 8 printed pages. This accounts for approx. 870 words …Length not stated
- reviewManuscripts can be in the form of (a) full length publications of Research; they should not be longer than 8 printed pages. This accounts for approx. 870 words …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship Policy
Authorship should incorporate and should be restricted to those who have contributed substantially to the work in one or more of the following categories: • Conceived of or designed study • Performed research • Analyzed data • Contributed new methods or models • Wrote the paper Back to top
Source ↗Publisher website ·- Conflicts of interest Conflict of interest
Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. This note should be added in a separate section before the reference list. If no conflict exists, authors should state: The authors declare that they have no conflict of interest. Back to top
Source ↗Publisher website ·- Data availability Data Availability
All original research must include a Data Availability Statement. Data Availability Statements should provide information on where data supporting the results reported in the article can be found. Statements should include, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. When it is not possible to share research data publicly, for instance when in…
Source ↗Publisher website ·- Publication ethics Ethical standards
Manuscripts submitted for publication must contain a statement to the effect that all human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. It should also be stated clearly in the text that all persons gave their informed conse…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Inflammopharmacology, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review
Double-anonymous peer review by at least two independent reviewers. Model summary
All manuscripts will be reviewed anonymously by at least two independent reviewers not connected (as much as this is practicable) with one another.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer International Publishing
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- 6 issues per year
- Founded
- 1991
- ISSN
- 0925-4692
- Electronic ISSN
- 1568-5608
- Latest issue on the website
- Volume 34, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Inflammopharmacology
What CAS zone is Inflammopharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Inflammopharmacology is in Zone 3 of Medicine, and in Zone 2 of the minor category Toxicology / Immunology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Inflammopharmacology?
The latest impact factor listed by LetPub is 6.37; CiteScore 8.7, h-index 92.
How long does peer review take at Inflammopharmacology?
Based on the dates recorded on 119 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 53 days (interquartile range 30–91 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Inflammopharmacology?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Harvard; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Inflammopharmacology based?
Of the 70 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (15), United States (12) and Australia (12). Counted from the institutions listed on the board page; for reference only.
Which databases index Inflammopharmacology?
According to LetPub and DOAJ records, Inflammopharmacology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Inflammopharmacology open access, and what is the APC?
Inflammopharmacology is a hybrid journal. For open-access publication: APC about USD 4,990.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .